Connection

Winfried Kern to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Winfried Kern has written about Antibodies, Monoclonal, Humanized.
Winfried Kern
Connection Strength
0.045
Antibodies, Monoclonal, Humanized
  1. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 03; 21(1):470.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.